Tominaga T, Nomura Y, Adachi I, Aoyama H, Nagao K, Mitsuyama S, Nakamura Y, Ogita M, Sano M, Takashima S
Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
Gan To Kagaku Ryoho. 1994 May;21(6):809-16.
A multi-institutional late phase II study of KW-2307 (vinorelbine), a new vinca alkaloid derivative, in advanced or recurrent breast cancer was conducted in 26 nationwide hospitals. KW-2307 was intravenously administered at a dose of 20 mg/m2 once weekly. Eighty among the enrolled 82 patients were eligible. The overall response rate was 30.0% (24/80) with 4 CR, 20 PR, 5 MR, 22 NC, 17 PD and 12 unevaluable patients. The major side effect was leucopenia, which was the dose-limiting factor in this study. Other subjective or objective side effects included general fatigue, nausea-vomiting, anorexia, paresthesia, fever and stomatitis, but none of them was serious.
一项关于新型长春花生物碱衍生物KW-2307（长春瑞滨）用于晚期或复发性乳腺癌的多机构II期后期研究在全国26家医院开展。KW-2307以20mg/m²的剂量静脉注射，每周一次。82名入组患者中有80名符合条件。总缓解率为30.0%（24/80），其中4例完全缓解，20例部分缓解，5例病情稳定，22例疾病未控，17例疾病进展，12例患者无法评估。主要副作用为白细胞减少，这是本研究中的剂量限制因素。其他主观或客观副作用包括全身乏力、恶心呕吐、厌食、感觉异常、发热和口腔炎，但均不严重。
